<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1613">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077400</url>
  </required_header>
  <id_info>
    <org_study_id>0115-09-EMC</org_study_id>
    <nct_id>NCT02077400</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotic in Treatment of Fingertip Amputation</brief_title>
  <official_title>The Use of Prophylactic Antibiotic in Treatment of Fingertip Amputation: A Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <authority>Israel: HaEmek medical center, helsinki board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fingertip amputation is a common injury. Considerable controversy exists as to whether
      prophylactic antibiotics are necessary for this injury. The investigators goal was to
      compare the rate of infections among subgroups with and without prophylactic antibiotic
      treatment. The study hypothesis was that infection rates were similar in the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>infection rate</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infection Rate After Fingertip Amputation</condition>
  <arm_group>
    <arm_group_label>no antibiotic</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cephazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefazoline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephazolin</intervention_name>
    <description>Cephazolin</description>
    <arm_group_label>Cephazolin</arm_group_label>
    <other_name>Cefamezine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fingertip amputation with bone exposed

        Exclusion Criteria:

          -  under the age of 18 years

          -  if the patient had diabetes

          -  oncological disorder

          -  immune deficiency

          -  bleeding disorder

          -  used steroids regularly

          -  presented with a grossly contaminated wound or other injury requiring antibiotic
             treatment

          -  were currently taking antibiotics, or had a previous allergic reaction to
             cephalosporins.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>guy rubin, MD</last_name>
    <phone>972-4-6494300</phone>
  </overall_contact>
  <location>
    <facility>
      <name>HaEmek medical center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guy rubin, MD</last_name>
    </contact>
    <investigator>
      <last_name>guy rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>March 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>guy rubin</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
